Pharmaceutical Technology on MSN6d
GSK to acquire Chimagen’s CMG1A46 for autoimmune diseaseGlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...
GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...
In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...
GSK inks agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline: London, UK Thursday, October 31, 2024, 10:00 Hrs [IST] GSK plc and Chimagen Bioscien ...
GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager ...
Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.
UK pharma major GSK is to buy CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from privately-held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback